

## New oncology reimbursements in Belgium

P. Specenier, MD, PhD<sup>1</sup>

### Overview of Belgian reimbursement news

*(Belg J Med Oncol 2016;10(1):44)*

**Lynparza®** (olaparib) can be reimbursed as a single agent for patients with recurrent platin-sensitive, PARP-naïve, BRCA-mutated high grade epithelial cancer of the ovary or fallopian tube or primary peritoneal cancer, with presence of a BRCA mutation, after at least two lines of prior platin-based chemotherapy.

**Zydelig®** (idelalisib) can be reimbursed in association with eight cycles of rituximab in patients with follicular

lymphoma refractory to at least two lines of prior therapy or in patients with chronic lymphatic leukaemia requiring treatment according to the IWCLL guidelines when a 17p deletion or TP53 mutation is present or after at least two prior therapies or at least one prior therapy including two cycles of an anti-CD20 immunotherapy who do not qualify for a purine-based treatment for specified reasons.

<sup>1</sup>Department of Oncology, University Hospital Antwerp, Edegem, Belgium.

Please send all correspondence to: T. Feys, MSc, MBA, Ariez International, Oude Houtlei 118, 9000 Ghent, Belgium, email: t.feys@ariez.com.

**Conflict of interest:** The author has nothing to disclose and indicates no potential conflict of interest.